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Abstract
Background: Intravenous (IV) iron supplementation is a 
standard maintenance treatment for hemodialysis (HD) pa-
tients, but the optimum dosing regimen is unknown. Meth-
ods: PIVOTAL (Proactive IV irOn Therapy in hemodiALysis pa-
tients) is a multicenter, open-label, blinded endpoint, ran-
domized controlled (PROBE) trial. Incident HD adults with a 
serum ferritin < 400 µg/L and transferrin saturation (TSAT) 
levels < 30% receiving erythropoiesis-stimulating agents 
(ESA) were eligible. Enrolled patients were randomized to a 
proactive, high-dose IV iron arm (iron sucrose 400 mg/month 
unless ferritin > 700 µg/L and/or TSAT ≥40%) or a reactive, 
low-dose IV iron arm (iron sucrose administered if ferritin 
<200 µg/L or TSAT < 20%). We hypothesized that proactive, 
high-dose IV iron would be noninferior to reactive, low-dose 
IV iron for the primary outcome of first occurrence of nonfa-
tal myocardial infarction (MI), nonfatal stroke, hospitaliza-
tion for heart failure or death from any cause. If noninferior-
ity is confirmed with a noninferiority limit of 1.25 for the haz-
ard ratio of the proactive strategy relative to the reactive 
strategy, a test for superiority will be carried out. Secondary 
outcomes include infection-related endpoints, ESA dose re-
quirements, and quality-of-life measures. As an event-driven 
trial, the study will continue until at least 631 primary out-
come events have accrued, but the expected duration of fol-
low-up is 2–4 years. Results: Of the 2,589 patients screened 
across 50 UK sites, 2,141 (83%) were randomized. At base-
This article is licensed under the Creative Commons Attribution-
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line, 65.3% were male, the median age was 65 years, and 79% 
were white. According to eligibility criteria, all patients were 
on ESA at screening. Prior stroke and MI were present in 8 
and 9% of the cohort, respectively, and 44% of patients had 
diabetes at baseline. Baseline data for the randomized co-
hort were generally concordant with recent data from the UK 
Renal Registry. Conclusions: PIVOTAL will provide important 
information about the optimum dosing of IV iron in HD pa-
tients representative of usual clinical practice. Trial Regis-
tration: EudraCT number: 2013-002267-25.
© 2018 The Author(s) 
Published by S. Karger AG, Basel
Introduction
Since the introduction of erythropoiesis-stimulating 
agents (ESAs) for the management of anemia in chronic 
kidney disease, intravenous (IV) iron has been widely 
used, particularly in hemodialysis (HD) patients where 
the average daily losses of iron typically exceed the oral 
absorption of iron [1, 2]. However, the maintenance IV 
iron regimen varies widely from one country to another, 
and indeed among dialysis centers in the same country. 
For example, much larger quantities of IV iron are ad-
ministered to HD patients in the United States, while IV 
iron is used very sparingly in Japanese HD patients [3]. 
Practice in the remainder of the world, including Europe, 
Australia, and Canada, is somewhere in the middle. 
The reason for this variation is the lack of any evi-
dence-base to inform clinical practice, as well as the fact 
that there are both advantages and disadvantages to the 
use of IV iron. The advantages of using a higher dosing 
regimen of IV iron include lower ESA dosage require-
ments. A number of landmark trials have demonstrated 
that higher ESA doses, targeting higher hemoglobin lev-
els, are associated with adverse clinical outcomes [4–
11]. In 1996, the Normal Hematocrit Cardiac Trial was 
halted prematurely because of concerns in the arm ran-
domized to normalization of hematocrit (i.e., 42%); sub-
sequent analysis confirmed that the higher hematocrit 
was associated with an approximately 30% increase in 
the risk of death or nonfatal myocardial infarction (MI) 
[10]. Data from the Correction of Hemoglobin and Out-
comes in Renal Insufficiency trial supported an associa-
tion between higher ESA doses and the primary com-
posite endpoint of death, heart failure (HF) hospitaliza-
tion, stroke, or MI [5]. A further post hoc analysis of the 
Correction of Hemoglobin and Outcomes In Renal In-
sufficiency data demonstrated that the cardiovascular 
toxicity of higher epoetin-alfa doses was separable from 
hemoglobin concentrations [6]. Finally, a two-fold in-
crease in stroke was independently associated with the 
use of darbepoetin alfa in the randomized placebo-con-
trolled Trial to Reduce Cardiovascular Events with 
Aranesp Therapy [8, 9]. In addition to cost savings, re-
duced ESA use afforded by higher doses of iron may 
reduce the risk of cardiovascular events observed in the 
aforementioned trials. Independent of ESA use, dialysis 
patients are at high risk for cardiovascular events and 
there is also strong evidence in patients with HF docu-
menting improvements in symptoms and in left ven-
tricular systolic function with IV iron repletion [12–16].
Conversely, there are concerns about the potential 
safety of high doses of IV iron. These have been reviewed 
extensively and were the focus of a Kidney Disease: Im-
proving Global Outcomes Controversies Conference on 
Iron Management [1]. These concerns include the poten-
tial for increased oxidative stress due to hydroxyl radical 
generation observed in some studies, which could exac-
erbate cardiovascular toxicity [1, 17–19]. Similarly, there 
is laboratory evidence that IV iron can enhance bacterial 
proliferation and reduce neutrophil killing of bacteria, 
generating concerns about an increased risk of infection 
[1, 18, 20]. Observational data on cardiovascular out-
comes and infection-related events associated with high-
dose IV iron use are conflicting [21, 22]. In any case, de-
spite adjusting for confounders, observational studies are 
subject to both known and unknown residual confound-
ing. A recent meta-analysis of randomized controlled tri-
als comparing high-dose versus low-dose IV iron in pa-
tients undergoing HD generated only 7 studies worthy of 
inclusion, and all of these had limitations, with regard to 
sample size and duration of follow-up [21, 23].
Thus, there has been a need for a scientifically rigor-
ous, adequately powered, randomized controlled trial 
with sufficient duration of follow-up. To fulfill this need, 
the Proactive IV irOn Therapy in hemodiALysis pa-
tients (PIVOTAL) trial was conceived. This study was 
designed to compare the effects of a proactive, high-dose 
IV iron regimen and reactive, low-dose IV iron regimen 
among incident (< 12 months) HD patients. We hypoth-
esized that proactive, high-dose IV iron would be non-
inferior to reactive, low-dose IV iron for the primary 
outcome of first occurrence of nonfatal MI, nonfatal 
stroke, hospitalization for HF, or death from any cause. 
PIVOTAL was also designed to provide insights on how 
these iron therapy approaches affect ESA dose require-
ments, red blood cell) transfusions, complications of 
HD treatment, quality of life, and relevant laboratory 
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were randomized to receive a proactive, high-dose IV iron or a 
reactive, low-dose IV iron regimen (Fig. 1). 
The primary efficacy measure of the PIVOTAL trial is the com-
posite of nonfatal MI, nonfatal stroke, hospitalization for HF, or 
death from any cause, analyzed as time to first event. All suspected, 
relevant, nonfatal events and deaths are adjudicated by a blinded 
Endpoint Adjudication Committee. Secondary endpoints include 
the individual components of the primary endpoint, ESA dose re-
quirements, and infection-related measures. Table 1 details the 
study endpoints. Patients will attend monthly follow-up visits until 
the required number of primary endpoint events has accrued (see 
power calculations). It was expected that the trial would take ap-
proximately 4 years to complete, allowing approximately 2 years for 
recruitment and approximately 2–4 years follow-up for each patient. 
biomarkers. This paper reports baseline data on all ran-
domized subjects and sets out the protocol for manage-
ment of subjects following randomization and through-
out follow-up.
Material and Methods
Study Design
PIVOTAL is a multicenter prospective, open-label, blinded 
endpoint, 2-arm randomized controlled trial among incident HD 
patients undergoing HD for < 12 months (EudraCT number 2013-
002267-25). Following a screening period of up to 4 weeks, patients 
IV iron 400 mg/month (withhold if ferritin >700 µg/L;
TSAT >40%)
Proactive, high-dose IV iron arm
Reactive, low-dose IV iron arm
IV iron only administered if ferritin <200 µg/L or TSAT<20%
Follow-up period with monthly visits (~2–4 years per patient)
New to HD
(0–12 months)
≤4 weeks
screening
On ESA
≥631 primary
endpoint events
(i.e., all-cause
mortality, MI,
stroke, or HF
hospitalization)
R
Fig. 1. PIVOTAL trial design. ESA, eryth-
ropoiesis-stimulating agents; HD, hemodi-
alysis; HF, heart failure; IV, intravenous; 
MI, myocardial infarction; TSAT, transfer-
rin saturation.
Table 1. PIVOTAL trial endpoints
Primary
A composite of nonfatal MI, nonfatal stroke, hospitalization for HF or death from any cause, analyzed as time-to-first event 
Secondary (efficacy) Secondary (safety)
– Total MI, stroke, hospitalization for HF and deaths, including first and 
recurrent events
– All-cause death
– First composite cardiovascular event (MI, stroke, and hospitalization for HF)
– Fatal or nonfatal MI
– Fatal or nonfatal stroke
– Heart failure hospitalization 
– ESA dose requirements
– Transfusion requirements
– EuroQol-5D (EQ-5D) 
– Kidney Disease Quality of Life (KDQOL) Instrument
– Vascular access thrombosis
– All-cause hospitalization
– Hospitalization for infection
– Time to first and number of infection episodes
Tertiary
– Cumulative dose of iron
– Hemoglobin level
– Serum ferritin level
– TSAT 
– Platelet count
– Serum albumin level
HF, heart failure; MI, myocardial infarction; TSAT, transferrin saturation.
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Eligibility
The eligibility criteria for the trial were designed to encourage 
enrollment of a real-world cohort. Adults with end stage renal dis-
ease started on chronic HD but treated for less than 12 months 
were eligible if they were on ESA therapy and had a serum ferritin 
level < 400 µg/L and a transferrin saturation (TSAT) < 30%. Pa-
tients who were consented within 12 months of commencing 
chronic HD but failed screening only because the ferritin levels 
were too high could be randomized only after their ferritin level 
had dropped to < 400 μg/L, provided they did not exceed 18 months 
of HD. Routine IV iron therapy was stopped at the time of consent. 
Patients were excluded if they had evidence of an active infection 
or other conditions in which iron therapy might pose safety con-
cerns. Table 2 details the full eligibility criteria for the trial. 
Screening
Written informed consent was obtained from potentially eli-
gible patients, and routine therapy with IV iron was discontin-
ued. At the screening visit, eligibility was assessed by the collec-
tion of demographic information, review of the medical history, 
and laboratory measurements. Patients meeting eligibility crite-
ria at the initial screening visit were transitioned from their rou-
tine iron regimen to the study regimen without any specified pe-
riod off iron therapy. Patients who failed initial screening, par-
ticularly those not meeting ferritin or TSAT inclusion criteria, 
could be re-screened and randomized after meeting eligibility 
criteria. 
Randomization and Intervention
Patients were randomized within 4 weeks of passing the 
screening requirements and were assigned to one of 2 treatment 
arms in a 1: 1 ratio using a web-based randomization system. Ran-
domization was based on randomly generated permuted blocks 
of variable sizes allocated within study sites and was stratified by 
the type of vascular access (dialysis catheter versus A-V fistulae) 
in use at the time of randomization, diabetic status, and time on 
dialysis at the time of initial screening (0–4 vs. 5–12 months). 
In both treatment arms, monthly iron doses were determined 
following monthly assessments of serum ferritin and TSAT. Iron (if 
not withheld) was administered during the first HD sessions in the 
week following the monthly assessment of the iron indices. All iron 
was administered as undiluted iron sucrose as a slow bolus injec-
tion or by IV infusion according to standard practice of the indi-
vidual center. Patients assigned to the proactive, high-dose IV iron 
arm were to receive IV iron sucrose 200 mg during each of the 3 
dialysis sessions at the start of the study, and during each of the first 
2 dialysis sessions of the week following the monthly blood tests for 
all subsequent months (i.e., 400 mg per month). If monthly testing 
demonstrated ferritin > 700 µg/L and/or TSAT ≥40%, IV iron was 
withheld for the month.
Patients randomized to the reactive, low-dose IV iron arm re-
ceived iron based on a pre-specified dosing schema, which permit-
ted the administration of iron only if patients were deemed “iron 
deficient” as assessed by serum ferritin levels and TSAT. If month-
ly testing demonstrated (1) ferritin > 200 µg/L and TSAT > 20%, (2) 
ferritin > 700 µg/L, or (3) TSAT ≥40%, iron was not administered 
that month. Provided that TSAT was < 40%, patients with ferritin 
< 100 µg/L received iron sucrose 200 mg during the first 2 dialysis 
sessions of the week; if ferritin was 100–200 µg/L, it was adminis-
tered only during the first dialysis session of the week. Patients 
with ferritin levels 201–700 µg/L and TSAT ≤20% received IV iron 
sucrose 100 mg during the first dialysis session of the week.
Table 2. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
– Age >18 years 
– Patients established on a chronic HD program for end-stage 
renal failure 
– Clinically stable per the judgment of the investigator
– 0–12 months since commencing HD 
– Patients who have switched to HD from peritoneal dialysis or 
have received previous HD or renal transplants are eligible to 
enter the study
– Ferritin <400 µg/L
– TSAT <30%
– On ESA therapy 
– Written informed consent
– Life expectancy <12 months per the judgement of the investigator 
– Living-donor transplant scheduled within 12 months
– Scheduled to switch to peritoneal dialysis or home HD 
– CRP >50 mg/L
– Active infection
– Current active malignancy (i.e., progressive untreated cancer or 
current treatment with cytotoxic chemotherapy)a
– Known HIV, active hepatitis B (i.e., HBV DNA positive), or active 
hepatitis C (i.e., HCV RNA is positive)
– Chronic liver disease and/or screening ALT or AST >3 × ULN 
– Advanced HF (i.e., NYHA class IV)
– Pregnancy or breast feeding
– History of acquired iron overload
– Previous severe hypersensitivity reactions to IV iron sucrose 
– Compromised ability to give written informed consent and/or to 
comply with study procedures
a Patients with basal cell or squamous cell carcinoma of the skin or cervical intraepithelial neoplasia and those on “prophylactic” 
maintenance treatment for cancer were permitted to enroll.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human im-
munodeficiency virus; NYHA, New York Heart Association; RNA, ribonucleic acid; ULN, upper limit of normal. 
Macdougall et al.Am J Nephrol 2018;48:260–268264
DOI: 10.1159/000493551
Follow-Up Assessments, Monitoring, and Ongoing Treatment
Patients were followed monthly for the duration of the trial. 
Laboratory tests assessed at each follow-up visit included hemo-
globin, platelets, ferritin, TSAT, and albumin. The occurrence of 
adverse events, the need for blood transfusions, the status of vas-
cular access, and the doses of ESA and iron were also recorded 
monthly. C-reactive protein concentrations were measured ev-
ery 3 months, while QoL measures (i.e., EQ-5D QoL and 
KDQOL) were completed at months 3, 6, 9, 12, and every 
6 months thereafter. Finally, red blood cell indices were collected 
at baseline and reassessed at 6-month intervals throughout the 
follow-up period. 
IV iron was dosed as described above throughout the duration 
of the trial. If per-protocol doses of IV iron were not administered 
at the first HD session(s) in the week after monthly testing, they 
were administered at the next attended dialysis session. Investiga-
tors were instructed to withhold iron if the patient developed an 
active infection deemed sufficient to contraindicate the use of IV 
iron. In such cases, iron therapy was resumed when the investiga-
tor judged it safe. 
Clinicians were instructed to adjust the dose of ESA therapy to 
maintain a target hemoglobin level of 10–12 g/dL. The maximum 
dose of ESA allowed was 30,000 international units of epoetin per 
week (or an average of 150 μg per week of darbepoetin alfa or me-
thoxypolyethylene glycol epoetin beta). 
Regulatory Considerations and Endpoint Adjudication
The PIVOTAL trial is being conducted in compliance with the 
principles of the Declaration of Helsinki (1996), the principles of 
Good Clinical Practice, and in accordance with all applicable regu-
latory requirements. The study protocol was approved by the 
South East Coast – Brighton and Sussex Research Ethics Commit-
tee, and the Medicines and Healthcare products Regulatory Agen-
cy. All patients provided written informed consent.
The primary outcome and the first 6 secondary outcomes (i.e., 
components of the primary outcome) are identified from reports 
of death, hospital admissions, or other serious adverse events re-
ported by the participant, study staff, treating physicians in pri-
mary or secondary care, or by computerized record linkage. All 
possible events will be documented, reviewed, and adjudicated by 
a blinded Endpoint Adjudication Committee (online suppl. Ap-
pendix 1; for all online suppl. material, see www.karger.com/
doi/10.1159/000493551) based on pre-specified criteria. An Inde-
pendent Data Monitoring Committee will review safety data, in-
cluding serious adverse events and the primary endpoint events, 
and will advise on acceptable continuation of the study, or wheth-
er the study should be stopped prematurely because of safety con-
cerns. 
Powering and Sample Size
Based on previous trials and registries (e.g., the AURORA trial 
[24] and the UK Renal Registry [25]), we expected the main com-
ponent of the primary outcome would be death. In AURORA, the 
1-year mortality rate was approximately 14%, and the annual rates 
of nonfatal MI and stroke were approximately 2 and 1% respec-
tively [24]. Similarly, the UK Renal Registry reported an 11.6% 
unadjusted 1-year mortality rate among incident HD patients (af-
ter 90 days) [25]. Therefore, initial sample size calculations as-
sumed a 3-year primary event rate of 50% (the expected average 
follow-up in the present trial) in the control group. 
Assuming a loss to follow-up rate of 10% (which includes renal 
transplantation), a total required sample size of 2,080 was calcu-
lated to allow rejection of a noninferiority hazard ratio (HR) limit 
of 1.20 with 80% power. After recruitment of 2,141 participants 
and blinded review of study endpoint rates, the steering committee 
decided to modify the noninferiority HR limit to 1.25, requiring a 
minimum of 631 first primary endpoints to provide at least 80% 
power (online suppl. Appendix 2). Such a change aligns the 
 PIVOTAL trial more closely with contemporary noninferiority 
clinical trials examining cardiovascular outcomes, including those 
reviewed by regulatory agencies in recent years [26, 27]. The 
change will also allow for completion of the trial in a reasonable 
time frame. 
Statistical Analysis
Baseline characteristics will be summarized by randomized 
treatment group and for the overall cohort. The primary analyses 
will use the intention-to-treat population, defined as all validly 
randomized participants with follow-up censored at the end of 
study, date of withdrawal from study consent, date of loss-to-fol-
low-up, or dates of renal transplantation, transfer to home dialysis 
or peritoneal dialysis, whichever comes first. Supporting analyses 
will be assessed in the per-protocol population, the population of 
randomized subjects that receive ≥1 trial dose of iron and had no 
major protocol deviations in relation to the inclusion/exclusion 
criteria. As a pre-specified sensitivity analysis, noninferiority will 
also be assessed in the intention-to-treat population, with addi-
tional censoring of participants after discontinuation of study drug 
(i.e., an on-treatment analysis).
The primary endpoint (i.e., the composite of all-cause death, 
nonfatal MI, nonfatal stroke, or hospitalization for HF) will ini-
tially be analyzed to assess noninferiority between the comparator 
(proactive, high-dose iron) and control arm (reactive, low-dose 
iron). All analyses will be conducted using cause-specific Cox pro-
portional hazards models including the stratification variables and 
the treatment variable. The HR for the treatment effect (proactive, 
high-dose arm compared to the reactive, low-dose arm) will be es-
timated with a 95% CI. A formal test (Wald statistic) of noninferi-
ority will test the null hypothesis that the HR treatment effect is 
≥1.25 against the alternative that HR < 1.25, with a required sig-
nificance level of 0.025 (one-sided test). If noninferiority is estab-
lished, a two-sided superiority test (Wald statistic) will then be 
carried out. For the outcome involving recurrent events, the cu-
mulative incidence of the composite events will be analyzed using 
the method of Ghosh and Lin [28] and the treatment groups will 
be compared using the proportional rate model of Lin et al. [29]. 
Additional analysis will be carried out on the composite nonfatal 
components of this outcome, using the same methodology. For the 
secondary outcomes involving time-to-first-event (i.e., compo-
nents of the primary endpoint), superiority analyses will be carried 
out as described above, with no requirement for any p value pen-
alty. For all time-to-first-event analyses, cumulative incidence 
functions will be constructed for each outcome type adjusting for 
the competing risks of transplantation, transfer to home or perito-
neal dialysis, and/or death as appropriate. The secondary analyses 
will be regarded as exploratory with no p value adjustments for 
multiple comparisons.
Pre-specified sub-groups are time on dialysis (0–4 vs. 5–12 
months), vascular access type (dialysis catheter vs. A-V fistulae), 
and diabetic status. Sub-group analyses will be carried out by add-
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ing the sub-grouping variable and its interaction with randomized 
treatment into the analysis models and testing for significance of 
the interaction terms. 
Cumulative ESA dose requirements will be summarized by 
study visit and compared between treatment groups at each visit 
and overall (scaled by duration of follow-up) using stratified Wil-
coxon rank sum tests. Time to first transfusion will be analyzed in 
a manner similar to the primary outcome. QoL scale and subscale 
scores will be compared via regression analyses adjusting for base-
line levels. Similar analyses will be used to examine the effects of 
therapy on hemoglobin, iron indices, platelets, and albumin con-
centrations. 
Safety outcomes of vascular access thrombosis and hospitaliza-
tion will be analyzed in a manner similar to the primary efficacy 
outcome. The number of infection episodes will be analyzed using 
a negative binomial regression model adjusting for duration of fol-
low-up. Adverse events will be summarized by Medical Dictionary 
for Regulatory Activities system organ class and preferred term 
and reported, but will not be subject to formal statistical testing.
Results
The PIVOTAL trial commenced in November 2013 
and patients were recruited from 50 sites across the Unit-
ed Kingdom (online suppl. Appendix 1). A total of 2,589 
patients were screened and 2,141 (83%) were randomized 
before recruitment ended on October 4, 2016. By far, the 
most common reason for screening failure was a serum 
ferritin above 400 μg/L, even after stopping IV iron. 
Among patients with high serum ferritin levels and/or 
TSAT levels at initial screening, 246 subsequently met el-
igibility criteria after a variable period of withholding iron 
(up to ∼10 months) and were then randomly assigned to 
a treatment arm. The required number of primary end-
points is projected to occur during mid-2018. At the time 
this manuscript was prepared, database lock has not oc-
curred, and all data remain blinded. 
Baseline Characteristics of Randomized Participants
Of the 2,141 randomized individuals, approximately 
two-thirds (65.2%) were male (Table 3). The median 
(lower and upper quartiles [LQ, UQ]) age was 65 (52, 75) 
years, with a range of 18–96 years. Seventy-nine percent 
of the randomized population was white. The median 
(LQ, UQ) weight was 80 (67, 95) kg and most patients 
were classified as overweight or obese (median [LQ, UQ] 
body mass index of 28 [24, 33] kg/m2). As detailed in Ta-
ble 3, the causes of end-stage renal disease were typical of 
a dialysis population. At baseline, 56% had dialysis access 
through an arteriovenous fistula, 3% through a polytetra-
fluoroethylene graft, and 41% through a central venous 
catheter. Although the majority of patients had a hemo-
Table 3. Baseline characteristics of PIVOTAL randomized popula-
tion
Characteristic Randomized participants 
(n = 2,141)
Age, years 65 (52, 75)
Gender, %
Male
Female
65.3
34.7
Ethnicity, %
White
Black
Asian
Other
79
9
9
3
Dialysis vintage, months
<5 months, %
≥5 months, %
4.8 (2.8, 8.2)
46
54
Diabetes, % 44
Hypertension, % 73
Prior MI, % 9
Atrial fibrillation, % 8
Prior stroke, % 8
Hyperlipidemia, % 25
Smoking status, %
Current
Former
Never
12
25
63
Weight, kg 80 (67, 95)
BMI, kg/m2 28 (24, 33)
Systolic BP, mm Hga 144 (128, 160)
Diastolic BP, mm Hga 73 (64, 83)
Hemoglobin, g/dL 10.6 (9.6, 11.5)
Ferritin, μg/L 216 (133, 304)
TSAT, % 20 (16, 24)
CRP, mg/L 6 (4, 14)
Albumin, g/L 36 (32, 39)
ESA dose, IU/weekb 8,000 (5,000, 12,000)
Primary cause of renal failure, %
Diabetic nephropathy
Glomerular disease
Hypertension 
Tubulointerstitial diseasec
Renovascular disease
Polycystic kidney disease
Other
Unknown
33.4
18.6
11.0
9.4
6.9
5.5
6.1
9.2
Continuous variables are shown as median (LQ, UQ).
a Blood pressure measurements represent pre-HD assessments. 
b ESA dose for darbepoetin and methoxypolyethylene glycol 
epoetin beta converted to IU/week using standard conversion fac-
tors. 
c Includes pyelonephritis, reflux nephropathy, and obstructive 
uropathy. 
BMI, body mass index; IU, international unit. 
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globin between 10 and 12 g/dL at baseline, > 25% of the 
cohort had a hemoglobin concentration < 10 g/dL. Con-
sistent with the inclusion criteria (i.e., ferritin < 400 ug/L), 
the median (LQ, UQ) ferritin level was 216 (133, 304) 
μg/L. According to inclusion criteria, all patients were re-
ceiving ESA, with 54% receiving darbepoetin alfa. The re-
maining patients were receiving epoetin alfa (25%), epo-
etin beta (17%), methoxy polyethylene glycol-epoetin 
beta (4%), and epoetin theta (< 0.01%). 
Prior Cardiovascular Events and Risk Factors
A history of major adverse cardiovascular events was 
rare among participants, reflecting the incident nature of 
the population; prior stroke and MI were present in 8 and 
9% of the cohort respectively. A history of HF or periph-
eral vascular disease was recorded for 4 and 9% of par-
ticipants respectively. Approximately 8% of the random-
ized population had a history of atrial fibrillation and 
one-quarter were diagnosed with hyperlipidemia. Nearly 
two-thirds of participants (63%) denied any history of 
cigarette smoking. As would be expected for a dialysis 
population, 73% of the cohort had hypertension. At base-
line, 44% of patients had diabetes.
Discussion
The 2 components of anemia management in HD pa-
tients are ESA therapy and IV iron. In contrast to ESA 
therapy, where several high-profile randomized con-
trolled trials inform clinical practice and clinical guide-
lines [8, 30–32], there are no trials that are sufficiently 
robust to inform physicians on the use of IV iron in HD 
patients, despite this being standard care. Because of the 
lack of evidence, there is a large disparity in the quantities 
of IV iron administered to patients maintained on chron-
ic HD [3]. There are both potential benefits and harms in 
using large amounts of IV iron in this patient population, 
such that there is clinical equipoise, which is an ideal, if 
not essential, prerequisite for a randomized controlled 
trial.
PIVOTAL was designed to investigate the noninferi-
ority of a proactive, high-dose IV iron regimen compared 
with a reactive, low-dose regimen and has 80% power to 
exclude a 25% increase in the HR for hard clinical end-
points including death and nonfatal cardiovascular 
events. In addition to the individual events making up the 
primary endpoint, there are also a number of important 
pre-specified secondary endpoints, including hospital-
izations, infections (infectious-related hospitalizations, 
deaths due to infections), ESA dose and transfusion re-
quirements, and QoL measures. We have completed re-
cruitment and are on course to reach the required num-
ber of endpoints in mid-2018. After appropriate clinical 
data management (e.g., data validation), the database will 
be locked, and statistical analysis will begin.
In selecting the iron doses for the proactive, high-dose 
and reactive, low-dose arms, there had to be a clear sepa-
ration between the treatment regimens. However, there 
are also ethical considerations and the need to be sensitive 
to what is presently regarded as acceptable practice. For 
the reactive, low-dose arm, the trial design was sensitive 
to the national and international guidelines on anemia 
management with respect to the lowest acceptable iron 
limits, namely, a ferritin of 200 μg/L and TSAT of 20%. 
Thus, it was intended that patients randomized to this 
arm should have their iron status maintained just above 
these thresholds, but not greatly exceeding them. For the 
proactive, high-dose arm, a safety cut-off beyond which 
no more IV iron should be given, was needed. In order to 
ensure investigator comfort and “buy-in,” and therefore 
success in this multicenter trial, a survey was conducted 
in 2012 at a national meeting of renal healthcare profes-
sionals in the United Kingdom. Attendees were asked 
about ferritin levels above which they would be con-
cerned about administering a significant amount of ad-
ditional IV iron on a monthly basis. The majority deci-
sion was a ferritin cutoff of 700 μg/L, and this was the 
selected threshold for the PIVOTAL study protocol. 
Above this level it was proposed that IV iron would be 
temporarily withheld for that month. There are inevitable 
limitations to selecting these thresholds, but the study is 
sufficiently powered, scientifically rigorous, and likely to 
inform preferred clinical practice for IV iron administra-
tion in the future.
The baseline demographic data of the PIVOTAL trial 
cohort align very closely with the “real world” dialysis 
population in the United Kingdom as detailed by the lat-
est data from the UK Renal Registry (online suppl. Table 
1). Baseline age, sex, body mass index, blood pressure, 
diabetes prevalence, and the proportion of current smok-
ers are all similar (R Steenkamp, unpublished data, June 
2018). There are slightly more white patients in the trial 
population (79 vs. 72%), possibly reflecting the known 
under-representation of ethnic minorities in clinical tri-
als [33–36]. Baseline laboratory variables are also repre-
sentative of the broader dialysis population in the United 
Kingdom, with the exception of the serum ferritin level 
which, as mandated by the PIVOTAL protocol, had to be 
< 400 μg/L to qualify for enrollment. It is reassuring to see 
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that the trial population is indeed representative of the 
“real world” dialysis population in the United Kingdom, 
and fairly similar to most dialysis populations worldwide 
[37–42]. There are, of course, a far higher proportion of 
white patients in the study, compared with dialysis popu-
lations in the United States and Asia, and some differ-
ences in the rates of comorbid conditions (e.g., diabetes), 
which are other minor limitations of the trial.
Despite these limitations, the study should be able to 
answer several important research questions. The pri-
mary analysis will be a noninferiority analysis to ascer-
tain whether the proactive, high-dose arm has any safe-
ty signals over the reactive, lower dose arm. If noninfe-
riority is satisfied, then the next statistical analysis will 
be a superiority analysis. Clearly, not all possible out-
comes need be positive or negative. Thus, results for a 
comparison of the primary endpoint may be different 
from results of an important secondary endpoint, such 
as infections. Nevertheless, the study has considerable 
power to examine these important primary and second-
ary endpoints.
In conclusion, PIVOTAL is the first rigorously de-
signed scientific study to examine the issue of IV iron 
dosing in HD patients. It is likely that the results of this 
trial, which are expected to be available towards the end 
of 2018, will yield information relevant to every dialysis 
physician and dialysis provider worldwide, for the benefit 
of patients.
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